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Gliomas are the most common type of primary central nervous system neoplasm. Astrocytomas are the most
prevalent type of glioma and these tumors may be influenced by sex steroid hormones. A literature review for
the presence of estrogen and progesterone receptors in astrocytomas was conducted in the PubMed database
using the following MeSH terms: ‘‘estrogen receptor beta’’ OR ‘‘estrogen receptor alpha’’ OR ‘‘estrogen receptor
antagonists’’ OR ‘‘progesterone receptors’’ OR ‘‘astrocytoma’’ OR ‘‘glioma’’ OR ‘‘glioblastoma’’. Among the
111 articles identified, 13 studies met our inclusion criteria. The majority of reports showed the presence of
estrogen and progesterone receptors in astrocytomas. Overall, higher tumor grades were associated with
decreased estrogen receptor expression and increased progesterone receptor expression.
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’ INTRODUCTION
Gliomas are the most common type of primary central
nervous system tumor and astrocytomas are the most
prevalent type of glioma. According to the World Health
Organization (WHO), these tumors may be classified into
two types: low-grade or benign (grades 1 and 2) and high-
grade or malignant (grades 3 and 4) (1,2).
High-grade glial tumors are the most common primary
malignant tumors of the central nervous system in adults.
Despite appropriate treatment with surgical excision, che-
motherapy and radiation therapy, the prognosis is poor (3,4).
Nevertheless, improved survival seems to depend on the
understanding and manipulation of pathways that regulate
aberrant tumor growth (1).
Estrogens are steroid hormones that exert important effects
on the reproductive and gastrointestinal systems, mammary
glands, skeletal and immune systems, and even the central
nervous system. The majority of estrogen effects are
mediated mainly by estrogen alpha (ERa) and beta (ERb)
receptors (5,6).
Progesterone participates in the regulation of several
reproductive processes, including ovulation and sexual
behavior. In synergism with estrogen, progesterone also
influences neuronal excitability, learning and neoplastic
proliferation of glial cells. These progesterone effects result
mainly from the interaction of this hormone with intra-
nuclear progesterone receptors (PR) (4).
There are two progesterone receptor isoforms: progester-
one receptor A (PR-A) and progesterone receptor B (PR-B),
which modify gene expression involved in cell proliferation,
angiogenesis and production of epidermal growth factor
(EGF) (7).
The effect of some anti-estrogenic drugs on glial tumor
cells in vitro has aroused interest in the study of possible
mechanisms of action for selective estrogen receptor mod-
ulators (SERMs), particularly tamoxifen, in these neoplasms
(8,9,10,11,12).
Therefore, based upon the scarcity of studies that have
investigated these receptors in glial cells, the current article
aimed to conduct a literature review of the PubMed database
to identify studies reporting the presence of estrogen and
progesterone receptors in glial tissue over the last 12 years.
’ MATERIALS AND METHODS
A PubMed database search was performed, focusing on
published articles that contained quantitative studies on ER
and PR expression in astrocytomas. The search was limited
to the English language. Only articles published in the lastDOI: 10.6061/clinics/2016(08)12
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12 years were included in this review because in this period
most reports involving immunohistochemistry and molecu-
lar biology on the subject were conducted. The articles
were required to contain original research data for study
inclusion. The search terms consisted of the following MeSH
terms: ‘‘estrogen receptor beta’’ OR ‘‘estrogen receptor alpha’’ OR
‘‘estrogen receptor antagonists’’ OR ‘‘receptors progesterone’’ OR
‘‘astrocytoma’’ OR ‘‘glioma’’ OR ‘‘glioblastoma.’’
The inclusion criteria were as follows: a) studies published
in English, b) studies in which patients with brain
astrocytomas were included, c) studies that investigated a
correlation between hormone receptors and astrocytomas
and d) studies that investigated a correlation between
SERMs and astrocytomas.
To expand the scope of the search, the reference lists of all
studies were inspected by two experienced authors. Studies
were excluded if they were irrelevant studies, duplicate
publications, articles with only abstracts available, case
reports/case series, editorials, commentaries, literature
reviews, letters to the editor and articles that were related
to types of glial tumors other than astrocytomas.
’ RESULTS
Selected studies
Of the 111 titles identified in the PubMed database
following the use of the keywords, only 42 satisfied the
inclusion criteria. Of these 42 articles, 29 articles were
excluded because 2 were duplicate articles, 6 were only
available as an abstract, 10 involved tumors that were not
astrocytomas, 2 were case reports, 4 were literature reviews
and 5 were considered irrelevant studies by the reviewers.
Thus, only 13 studies were used in the review (Figure 1).
Study characteristics
Four articles exclusively described the presence of ERb in
glial tumors and one specifically described ERb5 isoforms.
Two studies reported the presence of ERa in astrocytomas,
and only one reported the expression of both subtypes
(Table 1).
Four articles reported the presence of PR in astrocytomas
without specifying the subtypes. Only one study reported
PR-A and another study reported PR-B (Table 1).
With increasing histological malignancy of astrocytomas,
there was a decline in ERa expression described in two
studies and a decrease in ERb expression shown in another
four articles. With increasing cell dedifferentiation, an
increase in ERb5 and PR expression was described in two
different articles (Table 1).
Two studies showed that ER expression served as a
biomarker of a good prognosis; one study reported increased
ERa expression and the other reported increased ERb
expression (Table 1).
’ DISCUSSION
Gliomas are tumors derived from glial cells, such as
astrocytes, oligodendrocytes, microglia and ependymocytes.
Gliomas are the most common type of primary central
nervous system neoplasm, accounting for approximately
70-80% of all cases (2,3,4,13).
Depending to the cell of origin, these neoplasms are
termed astrocytomas, oligodendrogliomas, oligoastrocyto-
mas or ependymomas, with astrocytomas representing the
most common type of glioma. According to the WHO
classification, astrocytomas may be low-grade or benign and
high-grade or malignant, based on the following histologic
criteria: nuclear atypias, mitoses, cell proliferation and
presence of necrosis (2,4,12,12,13,18).
The main risk factors for gliomas are exposure to high
doses of ionizing radiation and the presence of rare genetic
conditions, such as neurofibromatosis and tuberous sclerosis
(15,16).
These tumors may present a variety of neurologic
manifestations, such as seizures, motor and sensory deficits
and changes in behavior. Complete surgical removal is
usually not possible due to the infiltrative nature of the
tumor and its location in critical areas of the brain (17).
According to Ho et al., who studied 21,085 glial tumors
in the Netherlands, the incidence of gliomas has increased in
the last 21 years, increasing from 4.9 cases per 100,000
inhabitants/year to 5.9 cases per 100,000 inhabitants/
year. This rise in glioma incidence may be the result
of greater awareness among physicians and the ease of
performing imaging tests. As a result, larger numbers of
patients are diagnosed, including those with asympto-
matic tumors (16).
High-grade gliomas have an annual incidence of 3.56 cases
per 100,000 inhabitants in the United States. There is a
predominance in males (3:1) and gliomas mainly affect
adults ranging from 40 to 60 years of age. Gliomas are
among the most aggressive primary brain tumors; even
when adequately treated with surgical resection, chemother-
apy and radiation therapy, patients with malignant gliomas
have a mean survival time of approximately 12 months. The
most recent advance in treatment is the use of temozolomide
as a chemotherapeutic agent. This drug has increased the
mean survival time by 2.5 months and survival after two
years by approximately 16% (3,4,20,21,22,23,24).
Glioblastoma multiforme (grade 4 of the WHO grading
system) relapses in 100% of cases. Recurrent tumors,
especially those treated previously with a combination of
surgery, radiation therapy and chemotherapy, are more
refractory to new therapeutic strategies (23).
Achieving prognostic improvements and more effective
treatment seems to depend on the understanding and
manipulation of molecular and genetic pathways thatFigure 1 - Search Flowchart.
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regulate the aberrant growth of these tumors. In particular,
biomolecular markers have introduced further information
concerning this topic in recent decades (2,21,25,26,27,28,29).
Regarding the clinical course of disease, two classes of
markers have been established in oncology: prognostic and
predictive markers. Prognostic markers detail the behavior of
the disease regardless of the treatment adopted, while
predictive markers provide information on the expected
progress if a certain intervention was performed (13,26).
In a systematic review of molecular and genetic markers in
the survival time of 14,678 patients with gliomas, Thuy et al.
reported the existence of four main biomarkers: O-6-
methylguanine methyltransferase (O-6-MGMT) methylation,
isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation, Ki-67/
MIB1 proliferation index and loss of heterozygosity on
chromosome 10/10q (LOH 10/10q) (29).
Steroid hormones exert important effects on the repro-
ductive system, gastrointestinal tract, mammary glands,
skeletal and immune systems, and even the central nervous
system (5,18).
Studies have demonstrated that steroid hormones have a
neuroprotective role in several neurological disorders, such
as Parkinson’s disease, Alzheimer’s disease, schizophrenia
and cerebrovascular accident (stroke). These neuroprotective
effects include increased myelination, decreased edema,
apoptosis and inflammation (18).
Hormones, mainly estrogens, may influence the develop-
ment and control of brain tumor growth by interacting with
their receptors or activating potentially oncogenic mediators.
Estrogens seem to have a protective effect on the develop-
ment of gliomas because they occur more commonly in men
than in women. In women, the incidence of gliomas increases
during the postmenopausal period, when estrogen levels are
low (3,14,18,30).
The majority of these effects are mediated by ERa and
ERb. The former was initially characterized and cloned in
Table 1 - Summary of the characteristics of selected studies.
Author Year Journal Country Conclusions
Batistatou, A et al. 2004 J Cancer Clin Oncol Greece ERb is mainly expressed in normal astrocytes and in astrocytes of
low-grade gliomas. Its presence decreases with increased malignancy of
these tumors.
Batistatou A et al. 2006 Journal of Neuro-
Oncology
Greece ERb expression is found in gliomas and oligodendrogliomas and ERb
expression tends to decrease with increased histological malignancy of
the tumor. Regression models and Kaplan-Meier curves showed better
prognosis and longer survival times for patients with ERb-positive
tumors.
Cabrera-Munoz E 2009 Journal of Steroid
Biochemistry &
Molecular Biology
Mexico The regulation of PR expression depends on the histological grade of
the astrocytoma. PR-A inhibits the effects of progesterone on growing
astrocytoma cells.
Cabrera-Mun˜oz E et al. 2011 Current Topics in
Medicinal Chemistry
Mexico PR expression is correlated with the histological malignancy of gliomas,
and PR-B is the predominant isoform in high-grade gliomas.
Sareddy G.R et al. 2012 Molecular Cancer
Therapeutics
USA ERb expression is found in normal brain tissue and in low-grade
gliomas. ERb expression decreases with the progression of glial tumors.
In high-grade gliomas, these receptors are found mainly in the
cytoplasm of tumor cells. ERb agonists inhibit the growth of gliomas in
cells in vivo.
Herna´ndez-Herna´ndez O.T et al. 2012 Journal of Steroid
Biochemistry &
Molecular Biology
Mexico Progesterone regulates VEGF and EGFR expression differently in
astrocytoma cells by interactions with PR and SRC-1.
Gonza´lez-Arenas A et al. 2012 Biochimica et Biophysica
Acta
Mexico Estrogen induces the growth of human astrocytomas by interaction
with ERa and recruitment of SRC-1 and SRC-3, regulating the expression
of genes responsible for cell proliferation and angiogenesis.
Wenjun Lia et al. 2013 Brain Research USA ERb5 is the main ERb isoform found in gliomas. Its expression is higher
in neoplasms than in normal brain tissue and increases with higher
grades of cell dedifferentiation.
Jimenez J.M.D et al. 2014 Journal of Neuro-
Oncology
Mexico There is a negative correlation between ERa expression and the
malignancy grade of gliomas.
There is a positive correlation between ERa expression and the survival
time of patients suffering from gliomas.
Liu C et al. 2014 Cancer Epidemiology China ERs are present in normal brain tissues and in gliomas. There is a
significant reduction in ERa and ERb expression with increased
histological malignancy of the tumor.
Germa´n-Castela´n L et al. 2014 Biomed Research
International
2014 Progesterone induces the proliferation and infiltration of human
anaplastic astrocytomas cells implanted in the rat motor cortex by
interaction with PR.
Atif F et al. 2015 Journal of Steroid
Biochemistry &
Molecular Biology
USA High doses of progesterone inhibit the in vitro growth of human
glioblastoma multiforme, mainly by inhibiting cell growth and tumor
angiogenesis and inducing apoptosis regardless of the interaction
with PR.
Gonza´lez-Arenas A et al. 2015 General Endocrinology Mexico Protein C kinase a (PKCa) phosphorylates PR, and these receptors
increase the genetic transcription and multiplication of astrocytomas.
ERa: Estrogen receptor alpha. ERb: estrogen receptor beta. ERb5: estrogen receptor beta 5. VEGF: Vascular endothelial growth factor. EGFR: epidermal
growth factor receptor. GDNF: glial cell line-derived neurotrophic factor. PR: progesterone receptor. PR-A: progesterone receptor A. SRC-1: steroid
receptor coactivator 1. SRC-3: steroid receptor coactivator 3.
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1986, and the latter was sequenced in 1996. These receptors
are highly homologous, despite being products of different
genes; ERa is located on chromosome 6q25.1 and ERb is
situated on chromosome 14q22-24 (6).
At least five ERb (ERb 1-5) isoforms have been identified.
These isoforms have an identical N-terminal sequence, but
the amino acid sequences diverge at amino acid 469 and
extend to the C-terminus. In vitro studies have shown
different transcription activities among these isoforms (31).
The function of ERa in several neoplasms has been widely
investigated, while the role of ERb in the pathophysiology of
cancer remains unknown. The presence of these receptors
decreases with higher tumor grades of astrocytomas,
suggesting that ERbmay play a neuroprotective role (5,6,30).
ERb agonists and SERMs inhibit glioma tumor growth and
promote tumor cell death. These findings suggest that
estrogens may decrease tumor proliferation by interacting
with nuclear receptors (30).
On the other hand, an in vitro study conducted with cell
cultures by González-Arenas et al. showed that estradiol
induced astrocyte growth through its interaction with ERa,
recruitment of SRC-1 and SRC-2 coactivators and regulation
of gene expression involved in the cell cycle, angiogenesis
and metastases (32).
The loss of ERb expression has been suggested as an
important step in estrogen-dependent tumor progression.
In breast tumors, high levels of ERb receptors are asso-
ciated with low-grade tumors, a favorable prognosis and a
good response to tamoxifen. However, this anti-proliferative
capacity has also been demonstrated in hormone-independent
tumors, e.g. colon and lung neoplasms. Different mecha-
nisms have been proposed for this anti-proliferative action,
such as inhibition of ERa transcription, inhibition of phase
S+G2/M and inhibition of hypoxia-inducible factor 1 (HIF1)
transcription activity (6,31).
Although few studies have examined ERb expression in brain
tissue, ERb is known to exist in neurons of the hippocampus,
astrocytes, pituitary tumors and glial tumors. However, the
specific function of ERb in the pathogenesis, progression and
prognosis of these neoplasms remains unknown (5,6,17).
In a study by Wenju Li et al., b5 was the most commonly
found isoform among glial ERb. In addition, ERb expression
was shown to increase with higher cell dedifferentiation,
contradicting previous studies. This increased ERb expres-
sion may have occurred as a result of hypoxia, which is
commonly encountered in gliomas (31).
The actions of steroid hormones may also be mediated by
coactivators, of which the family of p160 steroid receptor
coactivators (SRC) has been the most widely studied. This
family includes three members: SRC-1, SRC-2 and SRC-3.
SRC-1 is most commonly found in brain tissue, predomi-
nantly neurons, although some astrocytes may also express
this coactivator (33).
In astrocytomas, SRC-1 and SRC-3 are more abundant and
typically found in the cell nucleus. In comparison, SRC-2
shows low-level expression and is most commonly located in
extranuclear sites (31).
Progesterone participates in the regulation of various
reproductive processes, including ovulation and sexual
behavior. Nevertheless, it also influences neuronal excitabil-
ity, learning and the proliferation of brain tumors, such as
meningiomas, chordomas and astrocytomas (4,7).
There is abundant evidence showing that progesterone
plays a neuroprotective role after injury to the central and
peripheral nervous systems, limiting tissue damage or
improving functional prognosis after traumatic brain injury,
strokes, spinal cord injury, diabetic neuropathy and other
types of acute neurologic injuries (34).
Progesterone crosses the blood-brain barrier rapidly,
decreasing the inflammatory process and edema that
accompanies severe traumatic brain injury (23).
The actual mechanisms responsible for these effects remain
unknown. However, the major causes are the synthesis and
stimulated secretion of neuroprotective substances, including
neuronal growth factor (NGF), brain-derived neurotrophic
growth factor (BDNF) and glial cell line-derived neuro-
trophic factor (GDNF) (33).
Experimental studies have shown that progesterone is
capable of stimulating the infiltration and migration of
astrocytes in the rat cortex. This effect may be due to various
mechanisms, such as the increased expression of cell
adhesion proteins, modification of the cytoskeleton and
plasma membrane and even modification of voltage-
dependent ion channels (35).
In vitro studies indicate that progesterone promotes cell
proliferation in astrocytomas, as well as the expression of
genes that are important for tumor growth and dissemination,
e.g., cyclin D1, epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) (35,36).
However, there are several studies in the literature
confirming that progesterone has anti-proliferative and
apoptotic effects on ovarian, breast, endometrial and colon
tumors as well as gliomas (22).
According to Atif et al., high doses of progesterone inhibit
the growth of glioblastoma multiforme, both in vitro and in
animal experiments. This effect was shown to mainly involve
the inhibition of cellular proliferation and angiogenesis and
the induction of apoptosis (22).
Progesterone is derived from cholesterol and exerts its
effects through two major mechanisms, termed the classical
and non-classical pathways. The former involves an interac-
tion with intracellular PRs, while the latter requires the
participation of membrane receptors and ion channels. These
receptors are ligands of transcription factors for several genes
that are involved in the metabolism, development, reproduc-
tion and progression of the cell cycle (7,37).
Two PR isoforms have been described in humans, PR-A
and PR-B, and both isoforms have the same genetic origin.
They are differentially expressed in various brain regions and
may exert distinct functions in the same cell because they are
regulated by different promoters. In general, PR-B is a
stronger transcriptional activator than PR-A (7,15,35,36,38).
PRs have been found in several types of brain tumors, such
as meningiomas, chordomas, craniopharyngiomas and glio-
mas (15,20,39).
According to some studies, PR expression increases with
the histological malignancy of astrocytomas, different from
that observed with ERs. In addition, there is a predominance
of isoform B in high-grade gliomas (7,15,26,35,38,39,40,41).
PRs are regulated differently by estradiol and progesterone
in different cells and tissues. Normally, PR function is
increased (up-regulated) by estradiol and decreased (down-
regulated) by progesterone (7,30).
The action of estradiol is mediated by estrogen response
elements that are located in PR promoters. Progesterone
causes proteolysis of PRs by means of phosphorylation (24)
and this finding led us to conduct a review on ER and PR
expression in astrocytomas.
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Both ERa and ERb are expressed in astrocytomas, with a
predominance of isoform alpha. In the majority of studies,
the presence of both ERs was shown to decrease with
increasing histological tumor malignancy, suggesting a
neuroprotective role, particularly of the ER beta isoform.
Both PR-A and PR-B have been reported in astrocytomas,
with a predominance of the beta isoform. The presence of
both PRs was shown to increase with higher tumor grades.
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